About

Greywolf is a clinical-stage biotech company advancing novel antigen modulation technology which controls T cells to guide the immune system.

Our mission is to deliver a new class of treatments to improve the lives of people with cancers, autoimmune disorders, and infectious diseases.

Headquartered in Oxford, UK

Raised $131M from top venture capital funds and pharmaceutical companies

Founded in 2017 by Peter Joyce, former R&D Lead at Vertex Pharmaceuticals, and Tom McCarthy, former President and CEO of Spinifex Pharmaceuticals (acquired by Novartis for ~$700M).

Leadership

Chief Executive Officer & Co-founder

Darlene Deptula-Hicks

Chief Financial Officer

Chief Medical Officer

Chief Operating Officer & Chief Business Officer

Samantha Bucktrout

Head of Research

We're looking for talented individuals to join our award-winning team. Do you have what it takes?

Our board

Dedicated professionals committed to advancing healthcare solutions.

Co-founder and Non-executive Chair

Tracy Weightman

Associate Director at ICG

Investment Manager at BPC

Raphaël Wisniewski

Partner at Andera Partners (BioDiscovery)

Chief Executive Officer, Co-founder

Katya Smirnyagina

Senior Partner at Oxford Science Enterprises

Thierry Hercend

Industry Expert Director

Rabab Nasrallah

Investment Professional at Earlybird VC

Marie-Claire Peakman

Partner at Pfizer Ventures

General Partner at Canaan (West Coast)

Testimonials

"Greywolf are doing incredible things and they are totally going to change the game - best thing since sliced bread."

Big Time Existing Investor

Partner, Acme Investment

Recent awards

2024 Best Established Biotech (Finalist)

Series B Raise of the Year
(Finalist)

Existing investors

We are funded by top venture capital funds and pharmaceutical companies.

Discover how our therapies are reshaping treatment for various diseases and conditions.

Harnessing antigen modulation to empower T cells against diseases.